Wen Laboratory

Epigenetics and Transcription

Alterations in epigenetic landscape, together with genetic changes, are key events in initiation, progression and drug resistance of human cancers. The Wen Laboratory’s goal is to delineate how cancer cells, particularly pediatric cancers, exploit chromatin machinery to activate oncogenic or silent tumor suppressive gene expression programs, with the long-term goal of developing therapies to target epigenomic or epigenetic regulators for cancer treatment.

One of the lab’s current research projects is to characterize the role of ENL/MLLT1 in MLL-rearranged leukemia and other pediatric cancers. MLL-rearranged leukemia is a subtype of acute leukemia caused by MLL gene translocation, which accounts for about 70 percent of pediatric leukemia cases. Their previous work has identified the YEATS domain as a novel reader of histone acetylation (Li and Wen et al, Cell 2014) and uncovered that the ENL YEATS domain is critical for the expression of essential genes for disease maintenance in MLL-rearranged leukemia (Wan and Wen et al, Nature 2017). The lab is currently characterizing the role of ENL and its YEATS domain in tumor initiation and maintenance in a broad range of pediatric leukemias. We are also working on development of small molecules targeting the YEATS domain of ENL.

The ENL YEATS domain is frequently mutated in Wilms tumor, the most common pediatric kidney cancer. Another of the lab’s project is to investigate the molecular mechanism by which the ENL mutations contribute to Wilms tumor oncogenesis.

Dr. Wen and her team also study tumor suppressor ZMYND11, an adenovirus E1A-binding protein. She has previously identified that ZMYND11 is a bona-fide histone variant H3.3-specific reader of H3K36 methylation that regulates transcription elongation (Wen et al, Nature 2014).  Her lab is now generating a knockout mouse model to determine the role of ZMYND11 in tumor suppression in vivo.

Join Our Team

The laboratory of Dr. Hong Wen is seeking a highly motivated and skilled Postdoctoral Fellow to join our dynamic team. The Wen Lab employs multidisciplinary approaches to investigate epigenetic pathways in cancer, with the goal of developing innovative epigenetic therapies for cancer treatment. Applicants with experience in mouse models, epigenetics, or strong biological backgrounds with a keen interest in cancer epigenetics are especially encouraged to apply.

Contact Dr. Wen

Our Impact

We’re raising thousands to save millions.

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

  • 141 peer-reviewed papers published in 2025, 74 of which were in high-impact journals
  • 15 VAI-SU2C Epigenetics Dream Team clinical trials launched to date
  • 10 clinical trials and related projects supported by VAI through the International Linked Clinical Trials Program

Hong Wen, Ph.D.

Professor, Department of Epigenetics

Areas of Expertise

Chromatin, transcription, histone modifications, epigenetics, leukemia, pediatric cancers

Biography

Dr. Hong Wen earned her B.S. in biochemistry from Wuhan University and her Ph.D. in biochemistry and molecular biology from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, both with honors. She subsequently served as a postdoctoral fellow in the Department of Pathology at Stanford University. She joined the Department of Biochemistry and Molecular Biology at University of Texas MD Anderson Cancer Center as an assistant professor in 2008 and was promoted to associate professor in the Department of Epigenetics and Molecular Carcinogenesis in 2017. Dr. Wen joined Van Andel Institute in 2018 as an associate professor in the Department of Epigenetics and was promoted to professor in 2023. She is an epigenetics expert who investigates the molecular underpinnings of pediatric cancers, with a focus on how epigenetic dysregulation impacts gene expression and drives malignancy. She is also committed to developing new improved epigenetic therapies for cancer treatment. Dr. Wen is an awardee of Career Development Program Scholar from the Leukemia & Lymphoma Society.

Selected Publications

# Equal contributions * Co-corresponding authors

Jennifer Brooks

Senior Administrative Assistant I, Department of Epigenetics

Jeff Wang

Research Technician, Department of Epigenetics

Fan Xuan, Ph.D.

Research Scientist, Department of Epigenetics

Histone reader and epigenetic modifications in cancer

Yucong Yu, Ph.D.

Research Scientist, Department of Epigenetics